4-cycloakylaminopyrazolo pyrimidine NMDA/NR2B antagonists

A compound having the formula (I):

• wherein:
• R1 is selected from:
• unsubstituted or substituted with one or more substituents selected from:
• halogen, —R2, —O—R2, —CN, —N(R2)2,
• Y is selected from:
• wherein the CH2 moiety is bound to Z and the cyclopropyl moiety is bound to R1,
• —R3— and —R3—O—R3—, where C′ and C″ are each independently directly or indirectly bound to an R1 phenyl ring to form a 5 to 7 member fused ring;
• Z is absent or is selected from O, C1-6alkylene, C1-6alkenylene, C(O), S, SO, SO2, NR4, where R4 is hydrogen, C0-6alkyl or C0-6alkenyl, where said alkyl, alkenyl, alkylene or alkenylene is unsubstituted or is substituted with one or more substituents selected from:
• halogen, —R5, —O—R5, —CN, —N(R5)2;
• A and B are each independently C0-4alkyl, where a ring is formed comprising A and B, where each member of said ring is independently unsubstituted or substituted with one or more substituents selected from halogen, —R6, —O—R6, —CN, —N(R6)2;
• W is absent or is selected from O, C0-6alkylene, C0-6alkenylene, C(O), S, SO, SO2, NR7, where said alkyl, alkenyl, alkylene or alkenylene is unsubstituted or is substituted with one or more substituents selected from halogen, —R8, —O—R8, —CN, —N(R8)2;
• is unsubstituted or is substituted with one or more substituents selected from halogen, —R9, —O—R9, —CN, —N(R9)2;
• R2, R3, R4, R5, R6, R7, R8 and R9 are each independently hydrogen, C0-6alkyl, C0-6alkenyl unsubstituted or substituted with one or more halogen;
• or a pharmaceutically acceptable salt thereof, or an individual diastereomer thereof.